HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Supplemental data Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Getsios, D. Articles by Ishak, K. Search for Related Content PubMed PubMed Citation Articles by Getsios, D. Articles by Ishak, K.

Assessment of health economics in Alzheimer’s disease (AHEAD)

Galantamine treatment in Canada

From Caro Research (D. Gestios, G. Caro, and K. Ishak), Montreal, Quebec, Canada; Caro Research Institute (J.J. Caro), Concord, MA; and Division of General Internal Medicine, McGill University (J.J. Caro), Montreal, Quebec, Canada.

Address correspondence and reprint requests to J. Jaime Caro, Caro Research, 336 Baker Avenue, Concord, MA 01742; e-mail: jcaro{at}caroresearch.com

Background:— Given the high costs of caring for patients with AD in Canada, it is important to evaluate the costs of new therapies that halt or delay the advancement of AD, relative to the savings associated with delaying disease progression.

Methods:— The Assessment of Health Economics in Alzheimer’s Disease (AHEAD) model, which uses algorithms to predict the time until patients with AD require full-time care (FTC), was adapted to Canada to compare treatment with galantamine versus no pharmacologic treatment. Data from two clinical trials provided inputs into the algorithms, and forecasts were made for up to 10 years. Drug and health care costs were evaluated according to the stage of disease based on Quebec unit costs along with follow-up data from the Canadian Study of Health and Aging.

Results:— Galantamine is predicted to reduce the duration of FTC by almost 10%. Approximately 5.6 patients with mild to moderate disease must be placed on treatment to avoid one year of FTC, resulting in savings averaging $788 CAD ($528 USD) per patient. For patients with moderate disease, 3.9 patients must be placed on treatment to avoid one year of FTC, with savings predicted at $3718 CAD ($2533 USD) per patient.

Conclusion:— Galantamine cannot only potentially increase the time before patients require FTC, but may also lead to overall savings because treatment costs are offset by reductions in other health care expenditures.

This article has been cited by other articles:

				H. Feldman, S. Gauthier, J. Hecker, B. Vellas, M. Hux, Y. Xu, E.M. Schwam, S. Shah, and V. Mastey Economic evaluation of donepezil in moderate to severe Alzheimer disease Neurology, August 24, 2004; 63(4): 644 - 650. [Abstract] [Full Text] [PDF]

				J. L. Cummings Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations Focus, April 1, 2004; 2(2): 239 - 252. [Abstract] [Full Text] [PDF]

				D.L. Murman, Q. Chen, M.C. Powell, S.B. Kuo, C.J. Bradley, and C.C. Colenda The incremental direct costs associated with behavioral symptoms in AD Neurology, December 10, 2002; 59(11): 1721 - 1729. [Abstract] [Full Text] [PDF]

				M. S. Mendiondo, R. J. Kryscio, and F. A. Schmitt Models of progression in AD: Predicting disability and costs Neurology, September 25, 2001; 57(6): 943 - 944. [Full Text] [PDF]